Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ INHBB Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5145213
Description
Immunogen sequence: GWHTFPLTEA IQALFERGER RLNLDVQCDS CQELAVVPVF VDPGEESHRP FVVVQARLGD SRHRIRKRGL ECDGRTNL Antigen sequence identity: Mouse 97%; Rat 97%.
The inhibin beta B subunit joins the alpha subunit to form a pituitary FSH secretion inhibitor. Inhibin has been shown to regulate gonadal stromal cell proliferation negatively and to have tumour-suppressor activity. In addition, serum levels of inhibin have been shown to reflect the size of granulosa-cell tumors and can therefore be used as a marker for primary as well as recurrent disease. Because expression in gonadal and various extragonadal tissues may vary severalfold in a tissue-specific fashion, it is proposed that inhibin may be both a growth/differentiation factor and a hormone. Furthermore, the beta B subunit forms a homodimer, activin B, and also joins with the beta A subunit to form a heterodimer, activin AB, both of which stimulate FSH secretion.
Specifications
INHBB | |
Polyclonal | |
Unconjugated | |
INHBB | |
activin AB beta polypeptide; activin betaB; activin beta-B chain; INHBB; Inhibin beta B chain; inhibin beta B subunit; inhibin beta subunit B; inhibin beta-B; inhibin, beta B; Inhibin, beta-2 | |
Rabbit | |
Affinity chromatography | |
RUO | |
3625 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid | |
IgG |
Immunocytochemistry | |
0.2 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
P09529 | |
INHBB | |
Recombinant Protein Epitope Signature Tag (PrEST) antigen sequence. Antigen range: 225-302. | |
100 μL | |
Primary | |
Human | |
Antibody | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction